1,763 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Poinciana Advisors Group LLC

Poinciana Advisors Group LLC acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,763 shares of the medical research company's stock, valued at approximately $279,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the period. Massachusetts Financial Services Co. MA grew its position in Natera by 3.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock valued at $315,194,000 after acquiring an additional 85,236 shares during the period. Geode Capital Management LLC grew its position in Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock valued at $265,747,000 after acquiring an additional 143,825 shares during the period. Maverick Capital Ltd. grew its position in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock valued at $170,119,000 after acquiring an additional 269,706 shares during the period. Finally, Castle Hook Partners LP grew its position in Natera by 27.4% in the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company's stock valued at $144,734,000 after acquiring an additional 245,505 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 663 shares of the stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This represents a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company's stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 298,946 shares of company stock valued at $47,803,462. 7.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on NTRA shares. Guggenheim upped their price target on Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research report on Friday, January 17th. Morgan Stanley upped their price target on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group upped their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. StockNews.com upgraded Natera from a "sell" rating to a "hold" rating in a report on Wednesday. Finally, Royal Bank of Canada started coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price on the stock. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $178.12.

Natera Trading Up 3.1 %

NASDAQ:NTRA traded up $4.59 during mid-day trading on Wednesday, hitting $150.87. The company had a trading volume of 2,162,925 shares, compared to its average volume of 1,346,669. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The business's fifty day moving average is $162.76 and its two-hundred day moving average is $149.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm has a market cap of $20.40 billion, a P/E ratio of -85.72 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.